• With legislative approval for the legalized use of marijuana-based compounds for medical purposes in 29 states, we expect medical cannabinoid stocks to be a prominent investment theme in 2018.
• During the fourth quarter of 2017, cannabis stocks climbed sharply (North American Marijuana Index +137%) reflecting increased investor interest and positive fundamental tailwinds.
• News on ongoing and completed clinical studies should drive increasing investor interest in medical cannabinoid stocks.
• AXIM Biotechnologies is well positioned to benefit from the overall medical cannabinoid investment theme and is expected to achieve significant milestones during 2018.
The Medical Cannabinoid Space
2018 appears to be the year for transformative change in the medical cannabinoid industry. The fundamental trends are acting as tailwinds that potentially could last for years. Structural changes (such as state-level legislation, the proliferation of clinical studies and the growing social acceptance of cannabis investments) are stimulating a thematic-investment case for medical cannabinoid.
The ETF industry has reacted to the budding demand for this particular investment-themed ETF. Making its debut on the Toronto Stock Exchange in April 2017, the Horizons Medical Marijuana Life Sciences ETF